DTA CV and Metabolism, Discovery Research CV & Metabolic Diseases, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Basel, Switzerland.
Br J Pharmacol. 2012 Dec;167(7):1448-66. doi: 10.1111/j.1476-5381.2012.02090.x.
The mGlu(7) receptors are strategically located at the site of vesicle fusion where they modulate the release of the main excitatory and inhibitory neurotransmitters. Consequently, they are implicated in the underlying pathophysiology of CNS diseases such as epilepsy and stress-related psychiatric disorders. Here, we characterized a selective, potent and functional anti-mGlu(7) monoclonal antibody, MAB1/28, that triggers receptor internalization.
MAB1/28's activity was investigated using Western blot and direct immunofluorescence on live cells, in vitro pharmacology by functional cAMP and [(35) S]-GTPγ binding assays, the kinetics of IgG-induced internalization by image analysis, and the activation of the ERK1/2 by elisa.
mGlu(7) /mGlu(6) chimeric studies located the MAB1/28 binding site at the extracellular amino-terminus of mGlu(7) . MAB1/28 potently antagonized both orthosteric and allosteric agonist-induced inhibition of cAMP accumulation. The potency of the antagonistic actions was similar to the potency in triggering receptor internalization. The internalization mechanism occurred via a pertussis toxin-insensitive pathway and did not require Gα(i) protein activation. MAB1/28 activated ERK1/2 with potency similar to that for receptor internalization. The requirement of a bivalent receptor binding mode for receptor internalizations suggests that MAB1/28 modulates mGlu(7) dimers.
We obtained evidence for an allosteric-biased agonist activity triggered by MAB1/28, which activates a novel IgG-mediated GPCR internalization pathway that is not utilized by small molecule, orthosteric or allosteric agonists. Thus, MAB1/28 provides an invaluable biological tool for probing mGlu(7) function and selective activation of its intracellular trafficking.
mGlu(7) 受体位于囊泡融合部位,可调节主要兴奋性和抑制性神经递质的释放。因此,它们与 CNS 疾病(如癫痫和应激相关精神障碍)的潜在病理生理学有关。在此,我们对一种选择性、有效且具有功能的抗 mGlu(7) 单克隆抗体 MAB1/28 进行了描述,该抗体可触发受体内化。
使用 Western blot 和活细胞直接免疫荧光、体外药理学(通过功能性 cAMP 和 [(35)S]-GTPγ 结合测定)、通过图像分析测定 IgG 诱导内化的动力学以及 ELISA 测定 ERK1/2 的激活来研究 MAB1/28 的活性。
mGlu(7)/mGlu(6) 嵌合研究将 MAB1/28 的结合位点定位在 mGlu(7) 的细胞外氨基末端。MAB1/28 可强烈拮抗正构和变构激动剂诱导的 cAMP 积累抑制。拮抗作用的效力与触发受体内化的效力相似。内化机制通过百日咳毒素不敏感途径发生,不依赖于 Gα(i) 蛋白激活。MAB1/28 以与受体内化相似的效力激活 ERK1/2。受体内化需要二价受体结合模式,这表明 MAB1/28 调节 mGlu(7) 二聚体。
我们获得了证据表明,MAB1/28 触发了一种变构偏向激动剂活性,该活性激活了一种新型 IgG 介导的 GPCR 内化途径,该途径不被小分子、正构或变构激动剂利用。因此,MAB1/28 为研究 mGlu(7) 功能和其细胞内转运的选择性激活提供了宝贵的生物学工具。